| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.958 | 0.002 | 0.958 | Phosphatidylinositol 3-kinase delta inhibitor | 0.792 0.003 DBMET01387 | ||
| 0.726 | 0.026 | 0.726 | Antiinflammatory | 0.464 0.104 DBMET01387 | ||
| 0.69 | 0.004 | 0.69 | Phosphatidylinositol kinase inhibitor | 0.408 0.005 DBMET01387 | ||
| 0.664 | 0.007 | 0.664 | Immunomodulator | 0.532 0.019 DBMET01387 | ||
| 0.61 | 0.016 | 0.61 | Toll-Like receptor agonist | 0.504 0.031 DBMET01387 | ||
| 0.609 | 0.016 | 0.609 | Toll-Like receptor 7 agonist | 0.502 0.031 DBMET01387 | ||
| 0.403 | 0.015 | 0.403 | ErbB-1 antagonist | 0.286 0.037 DBMET01387 | ||
| 0.331 | 0.004 | 0.331 | Phosphatidylinositol 3-kinase beta inhibitor | 0.233 0.005 DBMET01387 | ||
| 0.282 | 0.005 | 0.282 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.12 0.012 DBMET01387 | ||
| 0.306 | 0.034 | 0.306 | EphB2 antagonist | |||
| 0.214 | 0.012 | 0.214 | Breast cancer-resistant protein inhibitor | 0.16 0.02 DBMET01387 | ||
| 0.193 | 0.028 | 0.193 | Epidermal growth factor receptor kinase inhibitor | 0.168 0.038 DBMET01387 | ||
| 0.186 | 0.045 | 0.186 | Protein kinase (CK1) inhibitor | |||
| 0.147 | 0.011 | 0.147 | CXC chemokine receptor antagonist | 0.087 0.032 DBMET01387 | ||
| 0.195 | 0.078 | 0.195 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.13 | 0.038 | 0.13 | Multidrug resistance-associated protein 1 inhibitor | |||
| 0.172 | 0.08 | 0.172 | MAP kinase kinase 5 inhibitor | |||
| 0.112 | 0.024 | 0.112 | CDK1/cyclin B1 inhibitor | |||
| 0.151 | 0.066 | 0.151 | MAP kinase 3 inhibitor | |||
| 0.117 | 0.034 | 0.12 | Epidermal growth factor antagonist | 0.12 0.033 DBMET01387 | DBMET01387 | |
| 0.095 | 0.013 | 0.095 | Cyclin B1 inhibitor | |||
| 0.103 | 0.022 | 0.103 | Adenosine A1 receptor antagonist | 0.08 0.028 DBMET01387 | ||
| 0.09 | 0.011 | 0.09 | Cyclin B2 inhibitor | |||
| 0.166 | 0.088 | 0.166 | CDC-like kinase 4 inhibitor | |||
| 0.141 | 0.064 | 0.141 | Aurora-C kinase inhibitor | |||
| 0.089 | 0.012 | 0.089 | Cyclin B inhibitor | |||
| 0.102 | 0.028 | 0.102 | Cyclin B3 inhibitor | |||
| 0.171 | 0.1 | 0.171 | Growth factor agonist | |||
| 0.098 | 0.028 | 0.098 | Adenosine A3 receptor antagonist | |||
| 0.095 | 0.03 | 0.095 | CDK2/cyclin E2 inhibitor | |||
| 0.068 | 0.005 | 0.068 | CXC chemokine 3 receptor antagonist | 0.058 0.008 DBMET01387 | ||
| 0.1 | 0.04 | 0.1 | ErbB-4 antagonist | |||
| 0.069 | 0.011 | 0.069 | DNA-dependent protein kinase inhibitor | 0.047 0.024 DBMET01387 | ||
| 0.116 | 0.058 | 0.116 | EphA2 antagonist | |||
| 0.16 | 0.105 | 0.16 | Clk dual-specificity kinase inhibitor | |||
| 0.182 | 0.128 | 0.182 | RNA-directed DNA polymerase inhibitor | |||
| 0.1 | 0.049 | 0.1 | Alpha 2d adrenoreceptor antagonist | |||
| 0.06 | 0.01 | 0.06 | Potassium channel subfamily K member 3 blocker | 0.038 0.015 DBMET01387 | ||
| 0.09 | 0.04 | 0.116 | ErbB-2 antagonist | 0.116 0.029 DBMET01387 | DBMET01387 | |
| 0.113 | 0.064 | 0.113 | Cyclin-dependent kinase 5 inhibitor | |||
| 0.109 | 0.061 | 0.109 | Cyclin-dependent kinase 1 inhibitor | |||
| 0.203 | 0.157 | 0.203 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.08 | 0.035 | 0.08 | Adenosine A2 receptor antagonist | |||
| 0.237 | 0.195 | 0.237 | Analgesic | |||
| 0.076 | 0.036 | 0.076 | CDK1/cyclin B inhibitor | |||
| 0.116 | 0.078 | 0.116 | TRKB antagonist | |||
| 0.086 | 0.053 | 0.086 | ErbB-3 antagonist | |||
| 0.061 | 0.031 | 0.066 | Phosphodiesterase II inhibitor | 0.066 0.026 DBMET01387 | DBMET01387 | |
| 0.068 | 0.038 | 0.068 | Adenosine A2a receptor antagonist | |||
| 0.059 | 0.03 | 0.059 | Phosphatidylinositol 3-kinase alpha inhibitor | |||
| 0.111 | 0.081 | 0.111 | Protein kinase (CK1) delta inhibitor | |||
| 0.11 | 0.082 | 0.11 | c-Src kinase inhibitor | |||
| 0.039 | 0.013 | 0.039 | Histone deacetylase class IIb inhibitor | 0.031 0.015 DBMET01387 | ||
| 0.039 | 0.013 | 0.039 | Histone deacetylase 6 inhibitor | 0.031 0.015 DBMET01387 | ||
| 0.055 | 0.029 | 0.055 | Antiviral (Hepatitis D) | |||
| 0.042 | 0.016 | 0.042 | Histone deacetylase class IV inhibitor | 0.034 0.02 DBMET01387 | ||
| 0.042 | 0.016 | 0.042 | Histone deacetylase 11 inhibitor | 0.034 0.02 DBMET01387 | ||
| 0.039 | 0.014 | 0.039 | Histamine H3 receptor agonist | |||
| 0.053 | 0.03 | 0.058 | Phosphodiesterase 2A inhibitor | 0.058 0.025 DBMET01387 | DBMET01387 | |
| 0.151 | 0.128 | 0.151 | Anticonvulsant | |||
| 0.052 | 0.031 | 0.052 | Adenosine A2b receptor antagonist | |||
| 0.035 | 0.015 | 0.035 | Histone deacetylase class II inhibitor | 0.028 0.02 DBMET01387 | ||
| 0.084 | 0.066 | 0.084 | NADH dehydrogenase inhibitor | |||
| 0.032 | 0.014 | 0.032 | NMDA 2D receptor antagonist | 0.027 0.019 DBMET01387 | ||
| 0.057 | 0.042 | 0.057 | Glutamate (mGluR1) antagonist | |||
| 0.123 | 0.108 | 0.123 | MAP3K9 inhibitor | |||
| 0.115 | 0.101 | 0.115 | CDC-like kinase 1 inhibitor | |||
| 0.087 | 0.074 | 0.087 | Phosphodiesterase 7B inhibitor | |||
| 0.019 | 0.007 | 0.019 | O6-alkylguanine-DNA alkyltransferase inhibitor | |||
| 0.087 | 0.076 | 0.087 | Ephrin antagonist | |||
| 0.054 | 0.045 | 0.054 | Cyclin E inhibitor | |||
| 0.072 | 0.064 | 0.072 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | |||
| 0.111 | 0.102 | 0.111 | Growth factor antagonist | |||
| 0.105 | 0.097 | 0.105 | Protein-tyrosine kinase Lyn inhibitor | |||
| 0.112 | 0.107 | 0.112 | Activin receptor-like kinase 2 inhibitor | |||
| 0.022 | 0.019 | 0.022 | Adenosine A1 receptor agonist | |||
| 0.116 | 0.112 | 0.116 | Src kinase inhibitor | |||
| 0.046 | 0.045 | 0.046 | CXC chemokine 1 receptor antagonist | |||
| 0.016 | 0.014 | 0.016 | Adenosine A3 receptor agonist | |||
| 0.027 | 0.044 | 0.036 | Kinesin antagonist | 0.036 0.026 DBMET01387 | DBMET01387 | |
| 0.027 | 0.044 | 0.036 | Kinesin-like protein 1 inhibitor | 0.036 0.026 DBMET01387 | DBMET01387 | |
| 0.047 | 0.47 | 0.122 | NOS3 expression enhancer | 0.122 0.111 DBMET01387 | DBMET01387 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |